Dieser Tagungsband enthält die Beiträge aller Vorträge und Posterpräsentationen des 14. Symposiums der Sektion Sportinformatik und Sporttechnologie der Deutschen Vereinigung für Sportwissenschaft (dvs) an der Technischen Universität Chemnitz (29.-30. September 2022). Mit dem Ziel, das Forschungsfeld der Sportinformatik und Sporttechnologie voranzubringen, wurden knapp 20 vierseitige Beiträge eingereicht und in den Sessions Informations- und Feedbacksysteme im Sport, Digitale Bewegung: Datenerfassung, Analyse und Algorithmen sowie Sportgeräteentwicklung: Materialien, Konstruktion, Tests vorgestellt. / This conference volume contains the contributions of all oral and poster presentations of the 14th Symposium of the Section Sport Informatics and Engineering of the German Association for Sport Science (dvs) at Chemnitz University of Technology (September 29-30, 2022). With the goal of advancing the research field of sports informatics and sports technology, nearly 20 four-page papers were submitted and presented in the sessions Information and Feedback Systems in Sport, Digital Movement: Data Acquisition, Analysis and Algorithms, and Sports Equipment Development: Materials, Construction, Testing.

Purpose: We determined the indication, outcome and risk factors of single and multiple hematopoietic stem cell transplantation(s) (HSCT) in children and adolescents mostly with advanced disease. Methods: Forty-one out of 483 patients (8.5%; median age 9 years) diagnosed at the University of Leipzig with haematological and oncological diseases required HSCT from 1999 to 2011. Results: Patients had overall survival (OS) of 63±10% and 63±16%, event-free survival (EFS) of 57±10% and 42±16%, relapse incidence (RI) of 39±10% and 44±18% and non-relapse mor-tality (NRM) of 4±4% and 13±9% at 10-years after one or more HSCT for allogeneic and autologous HSCT, respectively. One patient in complete remission (CR)1 and five with advanced disease received two HSCT. Four of the six patients maintained/achieved CR for a median of 13 months. Three died of progression and one of NRM. Two patients had a third HSCT and one survived in CR +231 days after HSCT. Risk factors for OS and EFS were disease stage at HSCT and EBMT risk-score. Center (paediatric or JACIE accredited paediatric/adult) was not a determinant for survival. Conclusion: Paediatric single and multiple HSCT are important curative approaches for high-risk malignant diseases with low NRM. Efforts to reduce high RI remain the major aim.:Bibliographic description 3 Introduction: 4 Infections 6 Veno-occlusive disease (VOD) 7 Graft rejection 7 Graft-versus Host Disease (GvHD) 8 Non-relapse mortality (NRM) 9 Relapse of the underling disease 9 Indications for HSCT 10 HSCT in Children. 10 Research questions: 12 Publication 13 Discussion 22 Future developments 25 References 26 Abbreviations 28 Summary 29 Zusammenfassung 33 Erklärung über die eigenständige Abfassung der Arbeit 38 Curriculum vitae 39 Acknowledgement 42

Purpose: We determined the indication, outcome and risk factors of single and multiple hematopoietic stem cell transplantation(s) (HSCT) in children and adolescents mostly with advanced disease. Methods: Forty-one out of 483 patients (8.5%; median age 9 years) diagnosed at the University of Leipzig with haematological and oncological diseases required HSCT from 1999 to 2011. Results: Patients had overall survival (OS) of 63±10% and 63±16%, event-free survival (EFS) of 57±10% and 42±16%, relapse incidence (RI) of 39±10% and 44±18% and non-relapse mor-tality (NRM) of 4±4% and 13±9% at 10-years after one or more HSCT for allogeneic and autologous HSCT, respectively. One patient in complete remission (CR)1 and five with advanced disease received two HSCT. Four of the six patients maintained/achieved CR for a median of 13 months. Three died of progression and one of NRM. Two patients had a third HSCT and one survived in CR +231 days after HSCT. Risk factors for OS and EFS were disease stage at HSCT and EBMT risk-score. Center (paediatric or JACIE accredited paediatric/adult) was not a determinant for survival. Conclusion: Paediatric single and multiple HSCT are important curative approaches for high-risk malignant diseases with low NRM. Efforts to reduce high RI remain the major aim.